Danaher (NYSE:DHR) Price Target Cut to $226.00 by Analysts at Evercore ISI

Danaher (NYSE:DHR - Free Report) had its price target reduced by Evercore ISI from $230.00 to $226.00 in a research report released on Tuesday,Benzinga reports. Evercore ISI currently has an outperform rating on the conglomerate's stock.

Several other equities research analysts have also recently issued reports on DHR. The Goldman Sachs Group cut their price target on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Citigroup reissued a "buy" rating on shares of Danaher in a report on Monday, April 7th. Deutsche Bank Aktiengesellschaft dropped their price target on Danaher from $240.00 to $235.00 in a research note on Thursday, June 5th. Jefferies Financial Group reduced their price objective on shares of Danaher from $260.00 to $230.00 and set a "buy" rating on the stock in a research note on Tuesday, April 22nd. Finally, HSBC decreased their price target on Danaher from $270.00 to $240.00 in a research note on Friday, April 25th. Four analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $248.00.

Danaher Stock Up 0.1%

DHR traded up $0.25 on Tuesday, hitting $200.93. 2,050,741 shares of the company were exchanged, compared to its average volume of 3,502,152. The stock's fifty day moving average is $195.74 and its 200-day moving average is $206.85. Danaher has a 12 month low of $171.00 and a 12 month high of $281.70. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.05 and a current ratio of 1.43. The company has a market cap of $143.80 billion, a PE ratio of 39.02, a PEG ratio of 2.82 and a beta of 0.77.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The firm had revenue of $5.74 billion for the quarter, compared to analyst estimates of $5.58 billion. Equities research analysts predict that Danaher will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Stockholders of record on Friday, June 27th will be given a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.64%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Insider Buying and Selling at Danaher

In related news, EVP Christopher Paul Riley sold 15,805 shares of the firm's stock in a transaction that occurred on Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president owned 15,179 shares of the company's stock, valued at $3,005,442. This trade represents a 51.01% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Chairman Steven M. Rales sold 1,250,000 shares of Danaher stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the sale, the chairman owned 3,105,808 shares of the company's stock, valued at approximately $611,036,665.92. The trade was a 28.70% decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 11.10% of the company's stock.

Institutional Trading of Danaher

Several large investors have recently modified their holdings of DHR. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate's stock worth $12,296,123,000 after acquiring an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Danaher by 3.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate's stock worth $4,016,404,000 after purchasing an additional 612,154 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Danaher by 2.4% in the fourth quarter. Geode Capital Management LLC now owns 13,358,206 shares of the conglomerate's stock valued at $3,056,996,000 after purchasing an additional 315,446 shares in the last quarter. Norges Bank purchased a new position in shares of Danaher during the fourth quarter valued at approximately $2,130,740,000. Finally, Bank of New York Mellon Corp grew its holdings in Danaher by 2.3% during the first quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate's stock worth $1,800,614,000 after buying an additional 194,466 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company's stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.